E
ITOS

Ergoteles’s iTeos Therapeutics ITOS Stock Holding History

Ergoteles’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,468
Closed -$790K – 1490
2022
Q4 		$790K Buy
+40,468
New +$791K 0.03% 544

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Ergoteles's ITOS Position: Q1 2023 in Review

Ergoteles sold out of iTeos Therapeutics (ITOS) in Q1 2023, closing a stake of 40,468 shares — an estimated $790K sold.

Ergoteles first reported a position in ITOS in Q4 2022 and held it in 1 quarter. The position peaked at $790K in Q4 2022. 153 funds tracked by Wall St. Rank hold ITOS as of Q1 2023.

  • Ergoteles reported no remaining iTeos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 40,468 iTeos Therapeutics shares in Q1 2023, an estimated $790K.
  • Ergoteles first reported a position in iTeos Therapeutics in Q4 2022 and held it in 1 quarter.
  • Ergoteles's iTeos Therapeutics position peaked at $790K in Q4 2022.
  • 153 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.